Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 20 of 20 publications.
Skip to main content
Craig T, Baptist AP, Anderson J, Zaragoza-Urdaz RH, Burnette AF, Kelbel TE, Riedl MA, Vanegas A, Boyle K, Bartsch JL, Darden C, Brown TM, Schultz BG, Blair C, Sing K, Fox D, Juethner S. Hereditary angioedema: patient health care experiences within underrepresented racial and ethnic groups in the United States. Ann Allergy Asthma Immunol. 2025 Apr;134(4):465-473.e. doi: 10.1016/j.anai.2025.01.007
Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Li D, Darden C, Sayeed S, Jackson L, Garbinsky D, Osman N. Patient-reported clinical and productivity outcomes from the longitudinal telotristat ethyl treatment registry. Poster presented at the 2021 Virtual Annual Symposium of the North American Neuroendocrine Tumor Society (NANETS); November 3, 2021.
Darden C, Price M, Ray D, Goldstein G, Goss D, Bennett L, Garbinsky D, Thota R. Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors. J Patient Rep Outcomes. 2021 Sep 7;5(1):82. doi: 10.1186/s41687-021-00355-5
Darden C, Joish VN, Price MA, Garbinsky D, Schwartz S, Warner C, Wason S, Lapuerta P. Patient-reported activity impairment, work productivity loss, and carcinoid syndrome outcomes: interim analyses of the XERMELO patient registry. Poster presented at the NANETS 2020 Multidisciplinary Net Medical Virtual Symposium; October 2, 2020.
Price MA, Joish VN, Schwartz S, Fish-Steagall A, Bennett L, Darden C, Tesfaye E, Arnold K, Wason S, Lapuerta P. Xermelo patient registry: improvements in clinical outcomes, patients satisfaction, and weight with telotristat ethyl in the real-world. Poster presented at the 2019 North American Neuroendocrine Tumor Society (NANETS) Conference; October 3, 2019. Boston, MA.
Darden C, Ray D, Goldstein G, Goss D, Garbinsky D, Bennett L, Price M, Thota R. Satisfaction survey of administration modes for Long-Acting (LA) Somatostatin Analog (SSA) therapy in patients with Neuroendocrine Tumors (NETS). Poster presented at the 2019 North American Neuroendocrine Tumor Society (NANETS) Conference; October 3, 2019. Boston, MA.
Darden C, Ray D, Goldstein G, Goss D, Price M, Thota R. Satisfaction survey of administration modes for long-acting somatostatin analog therapy in patients with neuroendocrine tumors: results of cognitive interviews with US-based patients and nurses. Poster presented at the 2019 European Neuroendocrine Tumor Society Annual Conference; March 6, 2019. Barcelona, Spain.
Darden C, Mitra D, McSorley D, Davis K, Band J, Iyer S. Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer. Future Oncol. 2019 Jan;15(2):141-50. doi: 10.2217/fon-2018-0531
Iyer S, Darden C, McSorley D, Davis K, Band J, Mitra D. Treatment satisfaction in young women receiving palbociclib combination therapies for advanced/metastatic breast cancer in multiple countries globally. Poster presented at the 4th ESO-ESMO Breast Cancer in Young Women International Conference; October 6, 2018. Lugano, Switzerland.
Joish VN, Price MA, Schwartz S, Stanley S, Bennett L, Darden C, Tesfaye E, Mobley Q, Arnold K, Wason S, Lapuerta P. Xermelo patient registry: a real-world evidence study evaluating patient-reported outcomes with Xermelo. Poster presented at the 2018 NANETS Annual Multidisciplinary NET Disease Symposium; October 4, 2018. Seattle, WA.
Mitra D, Darden C, McSorley D, Davis K, Band J, Iyer S. Patient reported treatment satisfaction with palbociclib combination therapies for HR+/HER2– advanced or metastatic breast cancer in multiple countries. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.
Darden C, Mitra D, McSorley D, Davis K, Band J, Iyer S. Patient-reported treatment satisfaction among women receiving palbociclib combination therapies for HR+/HER2- advanced or metastatic breast cancer in the United States. Poster presented at the 35th Annual Miami Breast Cancer Conference; March 8, 2018. Miami Beach, FL.
Marion S, Tzivelekis S, Darden C, Price MA, Sherif B, Garcia J, Kaye JA, Chandler D. "Same-day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale. Support Care Cancer. 2016 Sep;24(9):3889-96. doi: 10.1007/s00520-016-3193-3
Darden CM, Price MA, Kaye JA, Sherif BN, Marion S, Tzivelekis S, Garcia J, Chandler D. Same-day administration of pegfilgrastim following myelosuppressive chemotherapy: practices and rationale. Blood. 2015 Dec 3;126(23):5585. doi: 10.1182/blood.V126.23.5585.5585